Study of 124I-NM404 in Advanced Solid Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

12 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors

NCT00003768

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

AFP464 in Treating Patients With Advanced Solid Tumors

NCT00369200

Unspecified Adult Solid Tumor, Protocol Specific

TERMINATED PHASE1

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

NCT00925275

Solid Tumors

COMPLETED PHASE1

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

NCT06219499

Advanced Solid Tumor

WITHDRAWN PHASE1

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

NCT01125449

Sarcoma Adenocarcinoma Carcinoma +2 more

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

124I-NM404 is a new investigational agent being developed to better identify local tumors and cancerous tumors using imaging technologies such as positron emission tomography (PET) scans. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. 124I-NM404 is only taken up by the cancer cells, not the normal cells. Compared to traditional methods such as CT (computed tomography) or MRI (Magnetic resonance imaging), 124I-NM404 may help physicians more accurately see and evaluate cancerous tumors. This agent has been safely studied in animals and a limited number of human patients with lung cancer. This study is being done to determine the best dose to use and to fully evaluate the images that result from using this new agent.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.